PAPER Oomens JE, Moonen JE, Vos SJ, Beran M, Mateus P, De Deyn PP, van der Flier WM, Geerlings MI, Huisman MA, Ikram MA, Schram MT, Slagboom PE, Verschuren WM, Beekman M, Bermejo I, Birhanu M, Bron EE, Dekker A, Frentz I, Garst SJ, Jaarsma E, Kok AA, Marcolini S, Mei L, van Charante EP, Richard E, Schalkwijk CG, van Sloten TT, Teunissen CE, Twait EL, Verberk IM, Vonk JM, van de Waarenburg MP, Wolters FJ, Jansen WJ, Visser PJ
SEARCH RESULTS
347686 RESULTS
PAPER Ismail YA, Haitham Y, Walid M, Mohamed H, El-Satar YM
Efficacy of acetylcholinesterase inhibitors on reducing hippocampal atrophy rate: a systematic review and meta-analysis.
BMC Neurol. 2025 Feb 12;25(1):60. PubMed.PAPER Kijpaisalratana N, Phuah CL, Ament Z, Bhave VM, Garcia-Guarniz AL, Duskin J, Couch CA, Irvin MR, Kimberly WT, Alzheimer's Disease Neuroimaging Initiative, Alzheimer Disease Metabolomics Consortium
White matter hyperintensity severity modifies gut metabolite association with cognitive outcomes.
J Prev Alzheimers Dis. 2025 Feb 11;:100086. Epub 2025 Feb 11 PubMed.PAPER Chen J, Zhu Z, Xu F, Dou B, Sheng Z, Xu Y
Phosphodiesterase 4 Inhibition in Neuropsychiatric Disorders Associated with Alzheimer's Disease.
Cells. 2025 Jan 22;14(3) PubMed.PAPER Debatisse J, Leng F, Ashraf A, Edison P
Cortical Diffusivity, a Biomarker for Early Neuronal Damage, Is Associated with Amyloid-β Deposition: A Pilot Study.
Cells. 2025 Jan 21;14(3) PubMed.PAPER Brinza I, Stache BA, Mihasan M, Gorgan DL, El Raey MA, El-Kashak W, Eldahshan OA, Hritcu L
Sweroside Modulates Oxidative Stress and Neuroplasticity-Related Gene Expression in Scopolamine-Treated Zebrafish.
CNS Neurol Disord Drug Targets. 2025 Feb 6; Epub 2025 Feb 6 PubMed.PAPER Divya, Faruq M, Nazir SS, Kaushik P, Parvez S, Vohora D
Ganaxolone Reverses the Effect of Amyloid β-Induced Neurotoxicity by Regulating the Liver X Receptor Expression in APP Transfected SH-SY5Y Cells and Murine Model of Alzheimer's Disease.
J Neurochem. 2025 Feb;169(2):e70007. PubMed.PAPER De Vito AN, Kunicki ZJ, Joyce HE, Huey ED, Jones RN, Alzheimer's Disease Neuroimaging Initiative
Parallel changes in cognition, neuropsychiatric symptoms, and amyloid in cognitively unimpaired older adults and those with mild cognitive impairment.
Alzheimers Dement. 2025 Feb;21(2):e14568. PubMed.PAPER Xu Z, Ji Y, Wen C, Gan J, Chen Z, Li R, Lin X, Dou J, Wang Y, Liu S, Shi Z, Wu H, Lu H, Chen H
Tracer kinetic model detecting heterogeneous blood-brain barrier permeability to water and contrast agent in Alzheimer's disease and dementia with Lewy bodies.
Alzheimers Dement. 2025 Feb;21(2):e14529. PubMed.PAPER Liu Z, He Y, Cui S, Dang L, Zhang B, Wang J, Lu W, Huo K, Jiang Y, Chen C, Gao L, Wei S, Zhao Y, Hu N, Wang J, Lv H, Qu Q, Shang S
Hypertension moderates the relationship between plasma beta-amyloid and cognitive impairment: a cross-sectional study in Xi'an, China.
Front Aging Neurosci. 2025;17:1532676. Epub 2025 Jan 28 PubMed.PAPER Petersen RC, Graf A, Brady C, De Santi S, Florian H, Landen J, Pontecorvo M, Randolph C, Sink K, Carrillo M, Weber CJ
Operationalizing selection criteria for clinical trials in Alzheimer's disease: Biomarker and clinical considerations: Proceedings from the Alzheimer's Association Research Roundtable (AARR) Fall 2021 meeting.
Alzheimers Dement (N Y). 2025;11(1):e70038. Epub 2025 Feb 11 PubMed.PAPER Hajós M, Pandey K, Singer AC, Duong D, Bitarafan S, Shpokayte M, Malchano Z, Kern R, Lah JJ, Levey AI, Seyfried NT
CSF proteomics reveals changes in myelin and synaptic biology after Spectris treatment.
Alzheimers Dement (N Y). 2025;11(1):e70051. Epub 2025 Feb 11 PubMed.PAPER Terstege DJ, Jabeen S, Alzheimer's Disease Neuroimaging Initiative, Galea LA, Epp JR, Sargin D
SSRIs reduce plasma tau and restore dorsal raphe metabolism in Alzheimer's disease.
Alzheimers Dement. 2025 Feb;21(2):e14579. PubMed.PAPER Tomimoto H, Matsumoto M, Shiina H, Saeki Y, Niidome T, Nakamura Y
[Pathophysiology and Clinical Presentation of Amyloid-Related Imaging Abnormality Induced by Anti-Amyloid-β Antibody Lecanemab].
Brain Nerve. 2025 Feb;77(2):175-187. PubMed.PAPER Heywood A, Cichocki AC, Numerick JD, Dykins MM, Roth GE, Ulrich DM, Phillips MS, Cerny BM, Ovsiew GP, Robinson AD, Soble JR, Song W, Pliskin NH, Jennette KJ
Trail making test- part B discontinuation is associated with worse performance across multiple cognitive domains, but not with psychological distress.
J Clin Exp Neuropsychol. 2025 Feb 11;:1-13. Epub 2025 Feb 11 PubMed.Current Filters
- Date Range : All x